Panacea Life Sciences Holdings, Inc.
PLSH
SEC CIK 1552189
Follow Panacea Life Sciences
Weekly email: filings, results, news
Revenue, last quarter
$1.1M
+55.9% vs same quarter last year
Net income
−$1.4M
+19.3% vs same quarter last year
EPS, diluted
−$0.09
+25% vs same quarter last year
Operating cash flow
−$357.1K
−13.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY23 | $2.4M | −$8M |
| FY22 | $1.6M | −$9.1M |
| FY21 | $2.1M | −$4.8M |
| FY20 | $9M | −$5.2M |
| FY19 | $345.7K | −$10M |
| FY18 | $0 | −$4.3M |
| FY17 | $0 | −$3.9M |
| FY16 | $0 | −$1.6M |
| FY15 | $213 | −$358K |
| FY14 | $852 | −$296.6K |
| FY13 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY23 | 47% | −232.5% | −336.1% |
| FY22 | 24.4% | −347.4% | −561.9% |
| FY21 | 26.2% | −288.3% | −232.2% |
| FY20 | 22.2% | −58.3% | −58% |
| FY19 | −491.9% | −3087.5% | −2898.3% |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | −182761.5% | −168064.3% |
| FY14 | - | −49326.1% | −34808.8% |
| FY13 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY23 | −$1.6M |
| FY22 | −$2.6M |
| FY21 | −$4.1M |
| FY20 | −$10.8M |
| FY19 | −$6.3M |
| FY18 | −$465.8K |
| FY17 | - |
| FY16 | −$892.2K |
| FY15 | −$640K |
| FY14 | −$405.7K |
| FY13 | - |
- Panacea Life Sciences
- Healthcare median
Show the numbers
| Year | Panacea Life Sciences | Healthcare median |
|---|---|---|
| FY23 | −336.1% | −97.1% |
| FY22 | −561.9% | −128.5% |
| FY21 | −232.2% | −129.2% |
| FY20 | −58% | −136.5% |
| FY19 | −2898.3% | −133.7% |
| FY18 | - | −173.4% |
| FY17 | - | −176.7% |
| FY16 | - | −164.8% |
| FY15 | −168064.3% | −183.4% |
| FY14 | −34808.8% | −133% |
| FY13 | - | −88.5% |
News
No stories filed under Panacea Life Sciences yet - coverage appears here as the news feed clusters it.